Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 827-836

  Patnaik, Amita ^a   Weiss, Glen J ^b   Leonard, John E ^c   Rasco, Drewwarren ^a   Sachdev, Jasgit C ^d   Fisher, Terrence L ^c   Winter, Laurie A ^c   Reilly, Christine ^c   Parker, Robert B ^c   Mutz, Danielle ^a   Blaydorn, Lisa ^b   Tolcher, Anthony W ^a   Zauderer, Maurice ^c   Ramanathan, Ramesh K ^d  

^a Center for Cancer Care   (United States)

^b CANCER TREATMENT CENTERS OF AMERICA   (United States)

^c VACCINEX INC   (United States)

^d HonorHealth Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG; VX 15 2503; MONOCLONAL ANTIBODY; VX15-2503 MONOCLONAL ANTIBODY;

ABDOMINAL CANCER; ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; COLON CANCER; DECREASED APPETITE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INFUSION RELATED REACTION; LUNG CANCER; MALE; MYALGIA; NAUSEA; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; SOLID TUMOR; T LYMPHOCYTE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84964342401     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0431     Document Type: Article

References (27)

1. Peranzoni E, Rivas-Caicedo A, Bougherara H, Salmon H, Donnadieu E. Positive and negative influence of the matrix architecture. Cell Mol Life Sci 2013;70:4431-48.
2. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
3. Atreya I, Neurath MF. Immune cells in colorectal cancer: Prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 2008;8: 561-72.
4. Liz-ee G, OverwijkWW,Radvanyi L, Gao J, Sharma P,HwuP. Harnessing the power of the immune system to target cancer. Ann Rev Med 2013;64: 71-90.
5. Delaire S, Billard C, Tordjman R, Ch-edotal A, Elhabazi A, Bensussan A, et al. Biological activity of soluble CD100: Soluble CD100, similarly to HSemaIII, inhibits immune cell migration. J Immunol 2001;166:4348-54.
6. Ch'ng ES, Kumanogoh A. Roles of SEMA4D and plexin B1in tumor progression. Mol Cancer 2010;9:251-60.
7. Giraudon P, Vincent P, Vuaillat C, Verlaeten O, Cartier L, Marie-Cardine A, et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol 2004;172:1246-55.
8. Giraudon P, Vincent P, Vuaillat C. T-cells in neuronal injury and repair: Semaphorins and related T-cell signals. Neuro Mol Med 2005;7:207-16.
9. Worzfield T, Swiercs JM, Looso M, Straub BK, Sivaraj KK, Offermanns S. ErbB-2 signals through plexin-B1 to promote breast cancer metastasis. J Clin Invest 2012;122:1296-305.
10. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002;4:720-4.
11. Conrotto P, Valdembri SC, Serini G, Tamagnone L, Comoglio PM, Bussolino F, et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005;105:4321-9.
12. Witherden DA, WatanabeM, Garijo O, Rieder SE, Sarkisyan G, Cronin SJF, et al. The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal gd T cell function. Immunity 2012;37:314-25.
13. Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, et al. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci U S A 1996;93: 11780-5.
14. Basile JR,Castilho RM, Williams VP, Gutkind JS. Semaphorin4Dprovides a link between axon guidance processes and tumor-induced angiogenesis. Proc Natl Acad Sci U S A 2006;103:9017-22.
15. Campos M, Campos SG, Ribeiro GG, Eguchi FC, Da Silva SR, De Oliveira CZ, et al. Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively. Oncol Lett 2013;5:1527-35.
16. Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, et al. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci 2011;102:2029-37.
17. Evans E, Jonason A, Bussler H, Torno S, Veeraraghavan J, Reilly C, et al. Antibody blockade of Semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol Res 2015;3:689-701.
18. Leonard JE, Fisher TE, Winter L, Cornelius C, Seils J, Reilly C, et al. Nonclinical safety evaluation of VX15/2503: A humanized IgG4 anti-SEMA4D antibody. Mol Cancer Ther 2015;14:964-72.
19. Smith E, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, et al. SEMA4D compromises blood-brain barrier, activates microglia and inhibits remyelination in neurodegenerative disease. Neurobiol Dis 2015;73: 254-68.
20. Labrijn AF, Buijsse AO, Van Den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009;27:767-71.
21. Bourdage J, Cook C, FarringtonDL, Chain JS, Konrad RJ. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods 2007;327:10-7.
22. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17:1278-83.
23. Strossberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK. Prognostic validity of the American Joint Committee on cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 2013;31: 420-5.
24. Bergmann P, Body J-J, Boonen S, Boutsen Y, Devogelaer J-P, Goemaere S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosponate treatment in osteoporosis: A consensus document of the Belgian Bone Club. Int J Clin Pract 2009;63:19-26.
25. Beers SA, French RR, Chan HTC, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: IMPLICAtions for antibody selection. Blood 2010;24: 5191-201.
26. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Stalter S, et al. Phase I safety and pharmacokinetic study of recombinanthuman antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
27. Wang JS, Jing CQ, Shan KS, Chen YZ, Guo XB, Cao ZX, et al. Semaphorin 4D and hypoxia-inducible factor-1a overexpression is related to prognosis in colorectal carcinoma. World J Gastroenterol 2015;21: 2191-8.